HENGRUI PHARMA

📅 Upcoming

🕒 Recent(90d)

News

• Cardiac drug developer Braveheart banks more than $382M in IPO
  Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.
  biopharma_dive · 6h ago
• BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
  BMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.
  fiercebiotech · 6d ago
• Braveheart, Attovia join next wave of biotech IPOs
  The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.
  biopharma_dive · 21d ago
• Kailera says obesity pill succeeds in late-stage trial in China
  The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.
  biopharma_dive · 29d ago
• Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials
  The GLP-1 pill being developed by Hengrui Pharma and Kailera Therapeutics posted decent results in two late-stage China-based trials — one in obesity and the other in diabetes. But the safety profi…
  endpoints · 29d ago
• House bill aims to crack down on China biotech deals
  A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.
  biopharma_dive · 2mo ago
• STAT+: Hims’ sales miss as telehealth competition grows
  Bristol's partnership with Hengrui Pharma, Viiv loses HIV treatment case, and more biotech news from The Readout
  stat · 2mo ago
• Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
  The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.
  biopharma_dive · 2mo ago
• Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
  It's becoming Hengrui Pharma's world, and some Western drugmakers are just living in it. China's largest pharma company, which boasts one of the biggest pipelines in the industry, has lined up Bris…
  endpoints · 2mo ago
• STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
  Bristol Myers Squibb and China's Hengrui Pharma are teaming up to advance more than a dozen early-stage drugs, in a deal worth up to $15.2 billion.
  stat · 2mo ago